Vanguard Group
WINT

Vanguard Group’s Windtree Therapeutics WINT Stock Holding History

Vanguard Group’s Portfolio WINT Stock Details WINT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-46
Closed -$14.7K – 4445
2024
Q1 		$14.7K Hold
46
– – ﹤0.01% 4410
2023
Q4 		$29.9K Hold
46
– – ﹤0.01% 4416
2023
Q3 		$39.5K Buy
+46
New +$51K ﹤0.01% 4439
2023
Q1 		– Sell
-4
Closed -$28.6K – 4579
2022
Q4 		$28.6K Sell
4
-6
-60% -$53.3K ﹤0.01% 4478
2022
Q3 		$137K Sell
10
-3
-23% -$53.6K ﹤0.01% 4464
2022
Q2 		$243K Buy
13
+1
+8% +$29.5K ﹤0.01% 4443
2022
Q1 		$629K Sell
12
-3
-20% -$157K ﹤0.01% 4338
2021
Q4 		$1.08M Hold
15
– – ﹤0.01% 4250
2021
Q3 		$1.38M Buy
15
+1
+7% +$85.1K ﹤0.01% 4168
2021
Q2 		$1.43M Buy
14
+2
+17% +$195K ﹤0.01% 4067
2021
Q1 		$1.32M Buy
12
+6
+100% +$1.3M ﹤0.01% 3950
2020
Q4 		$1.42M Hold
6
– – ﹤0.01% 3743
2020
Q3 		$1.51M Buy
+6
New +$2.02M ﹤0.01% 3565

Other funds holding WINT

TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Vanguard Group's WINT Position: Q2 2024 in Review

Vanguard Group sold out of Windtree Therapeutics (WINT) in Q2 2024, closing a stake of 46 shares — an estimated $14.7K sold.

Vanguard Group first reported a position in WINT in Q3 2020 and held it in 13 quarters. The position peaked at $1.51M in Q3 2020. 1 fund tracked by Wall St. Rank holds WINT as of Q2 2024.

  • Vanguard Group reported no remaining Windtree Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Vanguard Group sold 46 Windtree Therapeutics shares in Q2 2024, an estimated $14.7K.
  • Vanguard Group first reported a position in Windtree Therapeutics in Q3 2020 and held it in 13 quarters.
  • Vanguard Group's Windtree Therapeutics position peaked at $1.51M in Q3 2020.
  • 1 fund tracked by Wall St. Rank held Windtree Therapeutics as of Q2 2024.

Based on Vanguard Group's 13F filing for Q2 2024, filed 13 Aug 2024.